Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UBT251 in Obese/Overweight Chronic Kidney Disease (CKD) Population
NCT07134335Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Jul 2030
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of UBT251 in chronic kidney disease (CKD), obesity and Overweight (3 arms). Primary endpoint: log-transformed urinary albumin:creatinine ratio at 24 weeks. Started Sep 2025; status: recruiting.
02
Drugs
UBT251
03
Conditions
chronic kidney disease (CKD)obesityOverweight
Beyond the preview
Go deeper on NCT07134335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134335.